Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
暂无分享,去创建一个
T. Barbui | A. Vannucchi | F. Passamonti | A. Tefferi | H. Gisslinger | F. Rodeghiero | J. Thiele | E. Rumi | A. Rambaldi | G. Finazzi | H. Kvasnicka | M. Ruggeri | E. Antonioli | I. Bertozzi | N. Gangat | A. Carobbio | V. Buxhofer-Ausch | Maria Luigia Randi
[1] C. Smith. Diagnostic tests (1) – sensitivity and specificity , 2012, Phlebology.
[2] M. Di Nisio,et al. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2012, Thrombosis research.
[3] Scott T. Miller,et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload , 2011, Pediatric blood & cancer.
[4] J. Freedman,et al. The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. , 2011, The Journal of clinical investigation.
[5] A. Kiani,et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse , 2011, Haematologica.
[6] T. Barbui,et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Ogawa,et al. Novel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN , 2011, American journal of hematology.
[8] P. Fu,et al. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] H. Gisslinger,et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. , 2011, Blood.
[10] L. Farrer,et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. , 2011, Blood.
[11] A. Tefferi,et al. Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients , 2011, American journal of hematology.
[12] L. Manco,et al. Chronic hemolytic anemia is associated with a new glucose-6-phosphate dehydrogenase in-frame deletion in an older woman. , 2011, Blood cells, molecules & diseases.
[13] A. Tefferi,et al. Autosomal monosomies among 24,262 consecutive cytogenetic studies: Prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities , 2011, American journal of hematology.
[14] A. Tefferi,et al. Circulating levels of MCP‐1, sIL‐2R, IL‐15, and IL‐8 predict anemia response to pomalidomide therapy in myelofibrosis , 2011, American journal of hematology.
[15] Steve Evans,et al. The DEDUCE Guided Query tool: Providing simplified access to clinical data for research and quality improvement , 2011, J. Biomed. Informatics.
[16] I. Buccimazza. Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities , 2011, World Journal of Surgery.
[17] P. Hokland,et al. Towards individualized follow-up in adult acute myeloid leukemia in remission. , 2011, Blood.
[18] M. Cazzola,et al. p53 lesions in leukemic transformation. , 2011, The New England journal of medicine.
[19] M. Boeckh,et al. Cytomegalovirus in hematopoietic stem cell transplant recipients. , 2011, Hematology/oncology clinics of North America.
[20] W. Stock,et al. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML , 2010, Bone Marrow Transplantation.
[21] V. Pinto,et al. Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: A long‐term follow‐up , 2010, American journal of hematology.
[22] Joel N Hirschhorn,et al. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation , 2010, Nature Genetics.
[23] W. Arcese,et al. Standard‐ versus high‐dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization , 2010, Transfusion.
[24] B. Tutschek,et al. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion , 2010, Haematologica.
[25] J. Mayer,et al. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations , 2010, American journal of hematology.
[26] A. Tefferi,et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.
[27] J. Mandrekar. Receiver operating characteristic curve in diagnostic test assessment. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] A. Tefferi,et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations , 2010, Leukemia.
[29] S. Thein,et al. Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. , 2010, Blood cells, molecules & diseases.
[30] M. Franchini,et al. Disseminated intravascular coagulation in hematologic malignancies. , 2010, Seminars in thrombosis and hemostasis.
[31] Elaine Coustan-Smith,et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.
[32] A. Tefferi,et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.
[33] M. Cazzola,et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.
[34] R. Hills,et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Stephen W. Hartley,et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. , 2010, Blood.
[36] D. Steensma,et al. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count , 2010, American journal of hematology.
[37] J. Freedman,et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. , 2010, Blood.
[38] J. Gabrilove,et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] L. Kasman,et al. A systematic approach to virus–virus interactions , 2010, Virus Research.
[40] Drew Provan,et al. International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.
[41] R. Adams,et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. , 2009, Blood.
[42] H. Wajcman,et al. A rare G6PD variant (c.383T>G; p.128Leu>Arg) with a molecular pathophysiological mechanism similar to that of G6PD A- (68Val>Met, 126Asn>Asp). , 2009, Blood cells, molecules & diseases.
[43] E. Jaffe,et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report , 2009, Haematologica.
[44] Serena Sanna,et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. , 2009, Blood.
[45] F. Passamonti,et al. Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype , 2009, American journal of hematology.
[46] Chad Garner,et al. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. , 2009, Human molecular genetics.
[47] O. Abdel-Wahab,et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.
[48] Katherine G. Evans,et al. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. , 2009, Archives of dermatology.
[49] M. Lathrop,et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. , 2009, Blood.
[50] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[51] A. Bayram,et al. Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[52] Martin Klabusay,et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. , 2009, Experimental hematology.
[53] D. Steensma,et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not , 2009, American journal of hematology.
[54] J. Thachil,et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.
[55] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[56] M. Levi. Disseminated intravascular coagulation in cancer patients. , 2009, Best practice & research. Clinical haematology.
[57] O. Frankfurt,et al. The coagulopathy of acute promyelocytic leukaemia revisited. , 2009, Best practice & research. Clinical haematology.
[58] F. Passamonti,et al. Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients , 2009, American journal of hematology.
[59] M. Farrall,et al. Genetic Variation on Chromosome 6 Influences F Cell Levels in Healthy Individuals of African Descent and HbF Levels in Sickle Cell Patients , 2009, PloS one.
[60] J. Wood. Cardiac iron across different transfusion-dependent diseases. , 2008, Blood reviews.
[61] H. Ni,et al. Fc-independent phagocytosis: implications for intravenous IgG therapy in immune thrombocytopenia. , 2008, Cardiovascular & hematological disorders drug targets.
[62] P. Sebastiani,et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. , 2008, Blood cells, molecules & diseases.
[63] E. Vichinsky,et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions , 2008, Transfusion.
[64] M. Hou,et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies , 2008, Haematologica.
[65] J. Hirschhorn,et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease , 2008, Proceedings of the National Academy of Sciences.
[66] H. Einsele,et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.
[67] A. Bergen,et al. Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders , 2008, Molecular vision.
[68] A. Boscolo,et al. Protein C concentrate to restore physiological values in adult septic patients , 2008, Intensive Care Medicine.
[69] Jin-Hwang Liu,et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation , 2008, Annals of Hematology.
[70] Po-min Chen,et al. Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation , 2008, International journal of hematology.
[71] S. Baker,et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels , 2008, Pediatric blood & cancer.
[72] E. Olson,et al. Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.
[73] K. Ataga,et al. β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability , 2007, British journal of haematology.
[74] Simon Heath,et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15 , 2007, Nature Genetics.
[75] L. Montaner,et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. , 2007, Clinical lymphoma & myeloma.
[76] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[77] P. Marks,et al. Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.
[78] W. Drew,et al. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients , 2007, Current opinion in infectious diseases.
[79] Drew Wl. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. , 2007 .
[80] T. Spector,et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults , 2007, Proceedings of the National Academy of Sciences.
[81] K. Kalies,et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region , 2007, Histopathology.
[82] D. Hommes,et al. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. , 2007, Trends in molecular medicine.
[83] F. Mandelli,et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. , 2007, Blood.
[84] Xiang Y. Han. Epidemiologic Analysis of Reactivated Cytomegalovirus Antigenemia in Patients with Cancer , 2007, Journal of Clinical Microbiology.
[85] J. Esteve,et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention , 2007, Leukemia.
[86] R. Go,et al. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. , 2006, Haematologica.
[87] E. Vichinsky,et al. Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell disease , 2006, British journal of haematology.
[88] D. Horn,et al. Bloodstream infections in hospitalized adults with sickle cell disease: A retrospective analysis , 2006, American journal of hematology.
[89] Dan M. Kluger,et al. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. , 2006, Mayo Clinic proceedings.
[90] J. Freedman,et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. , 2006, Blood.
[91] S. Opal,et al. Coagulation abnormalities in critically ill patients , 2006, Critical care.
[92] H. Wajcman,et al. Pyruvate kinase deficiency in France: a 3‐year study reveals 27 new mutations , 2006, British journal of haematology.
[93] K. Laczika,et al. Treatment of adult patients with sepsis‐induced coagulopathy and purpura fulminans using a plasma‐derived protein C concentrate (Ceprotin®) , 2006, Vox sanguinis.
[94] G. Fantuzzi,et al. Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1 , 2006, The Journal of Immunology.
[95] M. Levine,et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] D. Hockenbery,et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[97] Alessia Moro,et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology , 2006, Leukemia & lymphoma.
[98] A. Rosen,et al. Apoptosis and autoimmunity. , 2005, Current opinion in immunology.
[99] M. Duvic,et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.
[100] M. Fumagalli,et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program , 2005, Transplant infectious disease : an official journal of the Transplantation Society.
[101] A. Raj,et al. Cathlink® 20: A subcutaneous implanted central venous access device used in children with sickle cell disease on long‐term erythrocytapheresis—a report of low complication rates , 2005, Pediatric blood & cancer.
[102] F. Bennardello,et al. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[103] S Parodi,et al. Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[104] M. Levi,et al. Pathogenesis and treatment of DIC. , 2005, Thrombosis research.
[105] J. Bussel,et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies , 2004, American journal of hematology.
[106] D. Nelson,et al. Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.
[107] C. Dinarello,et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[108] H. Kantarjian,et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.
[109] G. Papanicolaou,et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[110] B. Olsson,et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura , 2003, Nature Medicine.
[111] Shirley A. Williams,et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. , 2003, Blood.
[112] P. Mulder,et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. , 2003, Critical care medicine.
[113] J. Freedman,et al. Platelets in hemostasis and thrombosis: role of integrins and their ligands. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[114] J. Thiele,et al. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients , 2003, Annals of Hematology.
[115] G. Gilkeson,et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. , 2003, The Journal of clinical investigation.
[116] G. Pamuk,et al. Overview of 321 patients with idiopathic thrombocytopenic purpura , 2002, Annals of Hematology.
[117] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[118] L. Medeiros,et al. Discrepancies in the immunophenotype of lymphoma cells in samples obtained simultaneously from different anatomic sites. , 2002, American journal of clinical pathology.
[119] G. Trinchieri,et al. Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.
[120] C. Skibola,et al. Central venous catheter complications in sickle cell disease , 2002, American journal of hematology.
[121] F B Taylor,et al. Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.
[122] J. Dhainaut,et al. Activated protein C versus protein C in severe sepsis , 2001, Critical care medicine.
[123] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[124] S. O’Brien,et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. , 2001, The Journal of infectious diseases.
[125] G. Tricot,et al. Cytomegalovirus infection and non‐neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma , 2001, British journal of haematology.
[126] B. Nieswandt,et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. , 2000, Blood.
[127] C. Fisher,et al. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases , 2000, Critical care medicine.
[128] R. Mcmillan. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. , 2000, Seminars in hematology.
[129] G. McDonald,et al. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. , 2000, The American journal of surgical pathology.
[130] P. Harmatz,et al. Severity of Iron Overload in Patients with Sickle Cell Disease Receiving Chronic Red Blood Cell Transfusion Therapy , 2000, Blood.
[131] M. Cappellini,et al. Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. , 2000, Bailliere's best practice & research. Clinical haematology.
[132] S. Au,et al. Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. , 2000, Structure.
[133] B. Nieswandt,et al. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. , 2000, Blood.
[134] Y. Lian,et al. [Preliminary study on relationship between different viral pathogenesis and disease prognosis in patients with severe viral hepatitis]. , 1999, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.
[135] J. Clive,et al. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance , 1999, Bone Marrow Transplantation.
[136] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[137] L. Luzzatto,et al. Solution of the structure of tetrameric human glucose 6-phosphate dehydrogenase by molecular replacement. , 1999, Acta crystallographica. Section D, Biological crystallography.
[138] M. Ertem,et al. Platelet autoantibodies in immune thrombocytopenic purpura. , 1998, Transfusion science.
[139] T. Howard,et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients , 1998, American journal of hematology.
[140] D. Hockenbery,et al. Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[141] F. Chisari,et al. Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice , 1998, Journal of Virology.
[142] C. Sabin,et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease , 1998, Bone Marrow Transplantation.
[143] H. Einsele,et al. Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. , 1997, The Journal of infectious diseases.
[144] Jerrold S. Levine,et al. Apoptosis and autoimmunity , 1997, Current opinion in nephrology and hypertension.
[145] B. Andersson,et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.
[147] T. Stevens-Ayers,et al. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. , 1996, The Journal of infectious diseases.
[148] T. Pearson,et al. Experience with the Port-A-Cath in sickle cell disease. , 1996, Clinical and laboratory haematology.
[149] M. Gauderer,et al. Long‐Term Central Venous Access in Patients with Sickle Cell Disease: Incidence of Thrombotic and Infectious Complications , 1995, Journal of pediatric hematology/oncology.
[150] M. Boeckh,et al. Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. , 1995, The Journal of infectious diseases.
[151] Scott T. Miller,et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. , 1995, The Journal of pediatrics.
[152] A. Hess,et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. , 1995, Journal of immunology.
[153] G. Trinchieri,et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. , 1995, Journal of immunology.
[154] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[155] J. Bland,et al. Statistics Notes: Diagnostic tests 3: receiver operating characteristic plots , 1994, BMJ.
[156] C. E. Jones,et al. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. , 1994, Blood.
[157] J. Silber,et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. , 1994, Blood.
[158] Sanfeliu,et al. [15 years later]. , 1993, Revista de enfermeria.
[159] C. McLaren,et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major , 1993, American journal of hematology.
[160] Richard J. Jones,et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. , 1992, Blood.
[161] A. Stansfeld. Lymph Node Biopsy Interpretation , 1992 .
[162] J. Silber,et al. A modified transfusion program for prevention of stroke in sickle cell disease. , 1992, Blood.
[163] B. Forget,et al. δβ Thalassemia and Hereditary Persistence of Fetal Hemoglobin , 1991 .
[164] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[165] S. Piantadosi,et al. INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.
[166] C. Slingluff,et al. Totally implantable intravenous catheters in the management of sickle cell anemia , 1988, American journal of hematology.
[167] V. Kiefel,et al. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. , 1987, Blood.
[168] F. Collins,et al. A point mutation in the Aγ-globin gene promoter in Greek hereditary persistence of fetal haemoglobin , 1985, Nature.
[169] J. Pizzuto,et al. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.
[170] A. Piga,et al. Cirrhosis associated with multiple transfusions in thalassaemia. , 1984, Archives of disease in childhood.
[171] R. Doberneck. The diagnostic yield of lymph node biopsy. , 1983, Archives of surgery.
[172] Hoppe Rt. Histologic variation in non-Hodgkin's lymphomas: commentary. , 1981 .
[173] S. Karpatkin. Autoimmune thrombocytopenic purpura. , 1980, The American journal of the medical sciences.
[174] H. Notopuro,et al. Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.
[175] H. Watson,et al. British Committee for Standards in Haematology , 1969 .
[176] A. Cardona,et al. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. , 2011, The Cochrane database of systematic reviews.
[177] Cardona Af,et al. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (Review) , 2011 .
[178] A. Kiani,et al. Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine , 2010, Leukemia.
[179] H. Saba,et al. Disseminated Intravascular Coagulation (DIC) in cancer. , 2009, Cancer treatment and research.
[180] C. Kitchens. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). , 2009, Hematology. American Society of Hematology. Education Program.
[181] D. Gilliland,et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.
[182] P. Hari,et al. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma , 2009, Bone Marrow Transplantation.
[183] T. Cole. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. , 2006, Biotechnology annual review.
[184] Ashley P Ng,et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. , 2005, Haematologica.
[185] Cameron S. Osborne,et al. The Corfu deltabeta thalassemia deletion disrupts gamma-globin gene silencing and reveals post-transcriptional regulation of HbF expression. , 2005, Blood.
[186] G. Fantuzzi,et al. The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo , 2005, Molecular medicine.
[187] L. Manco,et al. Two new glucose-6-phosphate dehydrogenase mutations causing chronic hemolysis. , 2005, Haematologica.
[188] P. Bierling,et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. , 2005, Haematologica.
[189] Ada Maria Florena,et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. , 2004, Haematologica.
[190] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[191] M. Levi,et al. Coagulation: consultative hemostasis. , 2002, Hematology. American Society of Hematology. Education Program.
[192] C. Thoburn,et al. Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[193] S. Heimfeld,et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. , 1999, Blood.
[194] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[195] G. Masera,et al. Growth and sexual maturation in thalassemia major. , 1985, The Journal of pediatrics.
[196] T. Huisman,et al. Two Independent Genetic Factors in the j9-Globin Gene Cluster Are Associated With High G7..Levels in the HbF of SS Patients , 1984 .
[197] R. Hoppe. Histologic variation in non-Hodgkin's lymphomas: commentary. , 1981, Cancer treatment reports.
[198] E. Beutler,et al. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. , 1968, Blood.